|
1
|
Sterbova H, Sevcikova P, Kvasnickova L,
Glatz Z and Slanina J: Determination of lignans in Schisandra
chinensis using micellar electrokinetic capillary
chromatography. Electrophoresis. 23:253–258. 2002.
|
|
2
|
He X, Lian L and Lin L: Analysis of lignan
constituents from Schisandra chinensis by liquid
chromatography-electrospray mass spectrometry. J Chromatogr A.
757:81–87. 1997.
|
|
3
|
Min HY, Park EJ, Hong JY, Kang YJ, Kim SJ,
Chung HJ, Woo ER, Hung TM, Youn UJ, Kim YS, Kang SS, Bae K and Lee
SK: Antiproliferative effects of dibenzocyclooctadiene lignans
isolated from Schisandra chinensis in human cancer cells.
Bioorg Med Chem Lett. 18:523–526. 2008.
|
|
4
|
Choi MS, Kwon KJ, Jeon SJ, Go HS, Kim KC,
Ryu JR, Lee JM, Han SH, Cheong JH, Ryu JH, Shin KH and Ko CY:
Schizandra chinensis alkaloids inhibit
lipopolysaccharide-induced inflammatory responses in BV2 microglial
cells. J Biomol Tech. 17:47–56. 2009.
|
|
5
|
Oh SY, Kim YH, Bae DS, Um BH, Pan CH, Kim
CY, Lee HJ and Lee JK: Anti-inflammatory effects of gomisin N,
gomisin J, and schisandrin C isolated from the fruit of
Schisandra chinensis. Biosci Biotechnol Biochem. 74:285–291.
2010.
|
|
6
|
Marek J and Slanina J: Gomisin N. Acta
Cryst. 54:1548–1550. 1998.
|
|
7
|
Opletal L, Sovova H and Bartlova M:
Dibenzo[a,c]cyclooctadiene lignans of the genus Schisandra:
importance, isolation and determination. J Chromatogr B Analyt
Technol Biomed Life Sci. 812:357–371. 2004.
|
|
8
|
Choi YW, Takamatsu S, Khan SI, Srinivas
PV, Ferreira D, Zhao J and Khan IA: Schisandrene, a
dibenzocyclooctadiene lignan from Schisandra chinensis:
structure-antioxidant activity relationships of
dibenzocyclooctadiene lignans. J Nat Prod. 69:356–359. 2006.
|
|
9
|
Kim SH, Kim YS, Kang SS, Bae K, Hung TM
and Lee SM: Anti-apoptotic and hepatoprotective effects of gomisin
A on fulminant hepatic failure induced by D-galactosamine and
lipopolysaccharide in mice. J Pharmacol Sci. 106:225–233. 2008.
|
|
10
|
Yim SY, Lee YJ, Lee YK, Jung SE, Kim JH,
Kim HJ, Son BG, Park YH, Lee YG, Choi YW and Hwang DY: Gomisin N
isolated from Schisandra chinensis significantly induces
antiproliferative and pro-apoptotic effects in hepatic carcinoma.
Mol Med Rep. 2:725–732. 2009.
|
|
11
|
Waiwut P, Shin MS, Inujima A, Zhou Y,
Koizumi K, Saiki I and Sakurai H: Gomisin N enhances TNF-α-induced
apoptosis via inhibition of the NF-κB and EGFR survival pathways.
Mol Cell Biochem. 350:169–175. 2011.
|
|
12
|
Mahmood Z and Shukla Y: Death receptors:
targets for cancer therapy. Exp Cell Res. 316:887–899. 2010.
|
|
13
|
Wu GS: TRAIL as a target in anti-cancer
therapy. Cancer Lett. 285:1–5. 2009.
|
|
14
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen
H, Shahrokh Z and Schwall RH: Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162.
1999.
|
|
15
|
Shankar S and Srivastava RK: Enhancement
of therapeutic potential of TRAIL by cancer chemotherapy and
irradiation: mechanisms and clinical implications. Drug Resist
Updat. 7:139–156. 2004.
|
|
16
|
Sheridan JP, Marsters SA, Pitti RM, Gurney
A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood
WI, Goddard AD, Godowski P and Ashkenazi A: Control of
TRAIL-induced apoptosis by a family of signaling and decoy
receptors. Science. 277:818–821. 1997.
|
|
17
|
MacFarlane M: TRAIL-induced signalling and
apoptosis. Toxicol Lett. 139:89–97. 2003.
|
|
18
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005.
|
|
19
|
Fandy TE and Srivastava RK: Trichostatin A
sensitizes TRAIL-resistant myeloma cells by downregulation of the
antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol.
58:471–477. 2006.
|
|
20
|
LeBlanc HN and Ashkenazi A: Apo2L/TRAIL
and its death and decoy receptors. Cell Death Differ. 10:66–75.
2003.
|
|
21
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003.
|
|
22
|
Takeda K, Stagg J, Yagita H, Okumura K and
Smyth MJ: Targeting death-inducing receptors in cancer therapy.
Oncogene. 26:3745–3757. 2007.
|
|
23
|
Zhou J, Lu GD, Ong CS, Ong CN and Shen HM:
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis
via p53-mediated death receptor 4 up-regulation. Mol Cancer Ther.
7:2170–2180. 2008.
|
|
24
|
Taniguchi H, Yoshida T, Horinaka M, Yasuda
T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T and Sakai
T: Baicalein overcomes tumor necrosis factor-related
apoptosis-inducing ligand resistance via two different
cell-specific pathways in cancer cells but not in normal cells.
Cancer Res. 68:8918–8927. 2008.
|
|
25
|
Prasad S, Ravindran J, Sung B, Pandey MK
and Aggarwal BB: Garcinol potentiates TRAIL-induced apoptosis
through modulation of death receptors and antiapoptotic proteins.
Mol Cancer Ther. 9:856–868. 2010.
|
|
26
|
Li X, Wang JN, Huang JM, Xiong XK, Chen
MF, Ong CN, Shen HM and Yang XF: Chrysin promotes tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced
apoptosis in human cancer cell lines. Toxicol In Vitro. 25:630–635.
2011.
|
|
27
|
Lee DH, Rhee JG and Lee YJ: Reactive
oxygen species up-regulate p53 and Puma; a possible mechanism for
apoptosis during combined treatment with TRAIL and wogonin. Br J
Pharmacol. 157:1189–1202. 2009.
|
|
28
|
Ishiguro K, Ando T, Maeda O, Ohmiya N,
Niwa Y, Kadomatsu K and Goto H: Ginger ingredients reduce viability
of gastric cancer cells via distinct mechanisms. Biochem Biophys
Res Commun. 362:218–223. 2007.
|
|
29
|
Frese S, Pirnia F, Miescher D, Krajewski
S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization
of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires
activation of ERK2. Oncogene. 22:5427–5435. 2003.
|
|
30
|
Lee KY, Park JS, Jee YK and Rosen GD:
Triptolide sensitizes lung cancer cells to TNF-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition
of NF-kappaB activation. Exp Mol Med. 34:462–468. 2002.
|
|
31
|
Inoue S, MacFarlane M, Harper N, Wheat LM,
Dyer MJ and Cohen GM: Histone deacetylase inhibitors potentiate
TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in
lymphoid malignancies. Cell Death Differ. 11(Suppl 2): S193–S206.
2004.
|
|
32
|
Palacios C, Yerbes R and Lopez-Rivas A:
Flavopiridol induces cellular FLICE-inhibitory protein degradation
by the proteasome and promotes TRAIL-induced early signaling and
apoptosis in breast tumor cells. Cancer Res. 66:8858–8869.
2006.
|
|
33
|
Ganten TM, Koschny R, Haas TL, Sykora J,
Li-Weber M, Herzer K and Walczak H: Proteasome inhibition
sensitizes hepatocellular carcinoma cells, but not human
hepatocytes, to TRAIL. Hepatology. 42:588–597. 2005.
|
|
34
|
Shi RX, Ong CN and Shen HM: Protein kinase
C inhibition and x-linked inhibitor of apoptosis protein
degradation contribute to the sensitization effect of luteolin on
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis in cancer cells. Cancer Res. 65:7815–7823. 2005.
|
|
35
|
Zhang S, Shen HM and Ong CN:
Down-regulation of c-FLIP contributes to the sensitization effect
of 3,3′-diindolylmethane on TRAIL-induced apoptosis in cancer
cells. Mol Cancer Ther. 4:1972–1981. 2005.
|
|
36
|
Son YG, Kim EH, Kim JY, Kim SU, Kwon TK,
Yoon AR, Yun CO and Choi KS: Silibinin sensitizes human glioma
cells to TRAIL-mediated apoptosis via DR5 up-regulation and
down-regulation of c-FLIP and survivin. Cancer Res. 67:8274–8284.
2007.
|
|
37
|
Galligan L, Longley DB, McEwan M, Wilson
TR, McLaughlin K and Johnston PG: Chemotherapy and TRAIL-mediated
colon cancer cell death: the roles of p53, TRAIL receptors, and
c-FLIP. Mol Cancer Ther. 4:2026–2036. 2005.
|
|
38
|
Jin Z, McDonald ER III, Dicker DT and
El-Deiry WS: Deficient tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) death receptor transport to the
cell surface in human colon cancer cells selected for resistance to
TRAIL-induced apoptosis. J Biol Chem. 279:35829–35839. 2004.
|
